PureTech Health plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PureTech Health plc
The US biotech saw a net loss last year despite increased sales and has decided to focus more on its wholly owned pipeline, which includes a safer formulation of a Roche pulmonary fibrosis product.
Over 100 biopharma companies piled onto public markets in 2021, raising a combined $21bn. A sharp cool off has left many trading well below their listing price. What does it mean for biotech financing in 2022?
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
The firm’s lead candidate has shown strong tolerability in an early-stage trial for idiopathic pulmonary fibrosis, sparking hopes for registration-enabling studies and a streamlined development plan.
- Medical Devices
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Other Names / Subsidiaries
- Vedanta Biosciences, Inc.
- Alivio Therapeutics, Inc.
- resTORbio, Inc.
- Tal Medical
- Vor Biopharma